Literature DB >> 19944585

On the use of hyperpolarized helium MRI for conformal avoidance lung radiotherapy.

C W Hodge1, Wolfgang A Tomé, S B Fain, S M Bentzen, M P Mehta.   

Abstract

We wanted to illustrate the feasibility of using hyperpolarized helium magnetic resonance imaging (HPH-MRI) to obtain functional information that may assist in improving conformal avoidance of ventilating lung tissue during thoracic radiotherapy. HPH-MRI images were obtained from a volunteer patient and were first fused with a proton density-weighted (PD(w)) MRI to provide corresponding anatomic detail; they were then fused with the treatment planning computed tomography scan of a patient from our treatment planning database who possessed equivalent thoracic dimensions. An optimized treatment plan was then generated using the TomoTherapy treatment planning system, designating the HPH-enhancing regions as ventilation volume (VV). A dose-volume histogram compares the dosimetry of the lungs as a paired organ, the VV, and the lungs minus the VV. The clinical consequences of these changes was estimated using a bio-effect model, the parallel architecture model, or the local damage (f(dam)) model. Model parameters were chosen from published studies linking the incidence of grade 3+ pneumonitis, with the dose and volume irradiated. For two hypothetical treatment plans of 60 Gy in 30 fractions delivered to a right upper-lobe lung mass, one using and one ignoring the VV as an avoidance structure, the mean normalized total dose (NTD(mean)) values for the lung subvolumes were: lungs = 12.5 Gy₃ vs. 13.52 Gy₃, VV = 9.94 Gy₃ vs. 13.95 Gy₃, and lungs minus VV = 16.69 Gy₃ vs. 19.16 Gy₃. Using the f(dam) values generated from these plans, one would predict a reduction of the incidence of grade 3+ radiation pneumonitis from 12%-4% when compared with a conventionally optimized plan. The use of HPH-MRI to identify ventilated lung subvolumes is feasible and has the potential to be incorporated into conformal avoidance treatment planning paradigms. A prospective clinical study evaluating this imaging technique is being developed.
Copyright © 2010 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944585      PMCID: PMC2975877          DOI: 10.1016/j.meddos.2009.09.004

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  29 in total

1.  Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer.

Authors:  M L Hernando; L B Marks; G C Bentel; S M Zhou; D Hollis; S K Das; M Fan; M T Munley; T D Shafman; M S Anscher; P A Lind
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

2.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Scott A Merrick; Dorota Gabrys; Ennapadam S Venkatraman; Chandra M Burman; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

3.  Normal and abnormal pulmonary ventilation: visualization at hyperpolarized He-3 MR imaging.

Authors:  H U Kauczor; D Hofmann; K F Kreitner; H Nilgens; R Surkau; W Heil; A Potthast; M V Knopp; E W Otten; M Thelen
Journal:  Radiology       Date:  1996-11       Impact factor: 11.105

4.  Treatment volume and tissue tolerance.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-04       Impact factor: 7.038

5.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.

Authors:  M Saunders; S Dische; A Barrett; A Harvey; G Griffiths; M Palmar
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

6.  Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation.

Authors:  A Jackson; G J Kutcher; E D Yorke
Journal:  Med Phys       Date:  1993 May-Jun       Impact factor: 4.071

7.  A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; K Stanley; P Rubin; S Kramer; L Brady; R Perez-Tamayo; G S Brown; J Concannon; M Rotman; H G Seydel
Journal:  Cancer       Date:  1980-06-01       Impact factor: 6.860

8.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

9.  A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

Authors:  J D Cox; N Azarnia; R W Byhardt; K H Shin; B Emami; T F Pajak
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

10.  Optimizing radiation treatment plans for lung cancer using lung perfusion information.

Authors:  Yvette Seppenwoolde; Martijn Engelsman; Katrien De Jaeger; Sara H Muller; Paul Baas; Daniel L McShan; Benedick A Fraass; Marc L Kessler; José S A Belderbos; Liesbeth J Boersma; Joos V Lebesque
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

View more
  11 in total

1.  Evaluating the Toxicity Reduction With Computed Tomographic Ventilation Functional Avoidance Radiation Therapy.

Authors:  Austin M Faught; Yuya Miyasaka; Noriyuki Kadoya; Richard Castillo; Edward Castillo; Yevgeniy Vinogradskiy; Tokihiro Yamamoto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-26       Impact factor: 7.038

2.  Evaluating Which Dose-Function Metrics Are Most Critical for Functional-Guided Radiation Therapy.

Authors:  Austin M Faught; Tokihiro Yamamoto; Richard Castillo; Edward Castillo; Jingjing Zhang; Moyed Miften; Yevgeniy Vinogradskiy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-08       Impact factor: 7.038

Review 3.  Imaging of lung function using hyperpolarized helium-3 magnetic resonance imaging: Review of current and emerging translational methods and applications.

Authors:  Sean Fain; Mark L Schiebler; David G McCormack; Grace Parraga
Journal:  J Magn Reson Imaging       Date:  2010-12       Impact factor: 4.813

Review 4.  Magnetic resonance imaging with hyperpolarized agents: methods and applications.

Authors:  Erin B Adamson; Kai D Ludwig; David G Mummy; Sean B Fain
Journal:  Phys Med Biol       Date:  2017-04-06       Impact factor: 3.609

Review 5.  Functional imaging of the lungs with gas agents.

Authors:  Stanley J Kruger; Scott K Nagle; Marcus J Couch; Yoshiharu Ohno; Mitchell Albert; Sean B Fain
Journal:  J Magn Reson Imaging       Date:  2015-07-27       Impact factor: 4.813

6.  To Find a Better Dosimetric Parameter in the Predicting of Radiation-Induced Lung Toxicity Individually: Ventilation, Perfusion or CT based.

Authors:  Lin-Lin Xiao; Guoren Yang; Jinhu Chen; Xiaohui Wang; Qingwei Wu; Zongwei Huo; Qingxi Yu; Jinming Yu; Shuanghu Yuan
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 7.  Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision.

Authors:  In-Jae Oh; Sung-Ja Ahn
Journal:  Radiat Oncol J       Date:  2017-03-31

8.  Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial.

Authors:  Douglas A Hoover; Dante Pi Capaldi; Khadija Sheikh; David A Palma; George B Rodrigues; A Rashid Dar; Edward Yu; Brian Dingle; Mark Landis; Walter Kocha; Michael Sanatani; Mark Vincent; Jawaid Younus; Sara Kuruvilla; Stewart Gaede; Grace Parraga; Brian P Yaremko
Journal:  BMC Cancer       Date:  2014-12-11       Impact factor: 4.430

Review 9.  The potential for an enhanced role for MRI in radiation-therapy treatment planning.

Authors:  P Metcalfe; G P Liney; L Holloway; A Walker; M Barton; G P Delaney; S Vinod; W Tome
Journal:  Technol Cancer Res Treat       Date:  2013-04-24

10.  Magnetic resonance imaging biomarkers of chronic obstructive pulmonary disease prior to radiation therapy for non-small cell lung cancer.

Authors:  Khadija Sheikh; Dante P I Capaldi; Douglas A Hoover; David A Palma; Brian P Yaremko; Grace Parraga
Journal:  Eur J Radiol Open       Date:  2015-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.